Outcomes: Changing Drug Distribution's Cardinal Rule
Drug distributors are re-defining their role in the new health care delivery system, moving from anonymous product suppliers to providing greater value through enhanced service capabilities. Cardinal Health is among the leaders of wholesaling's new breed, moving closer to the hospital and establishing new relationships with pharmaceutical companies. Cardinal's latest venture, an outcomes data program called Jericho, could be a major step toward shedding the wholesaler's product-neutral label, putting distributors in the role of influencing drug selection and moving market share.
You may also be interested in...
Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker